CRNX
Price
$55.99
Change
-$0.44 (-0.78%)
Updated
Jan 16 closing price
Capitalization
5.74B
45 days until earnings call
Intraday BUY SELL Signals
NAMS
Price
$31.65
Change
-$0.18 (-0.57%)
Updated
Jan 16 closing price
Capitalization
3.59B
45 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRNX vs NAMS

Header iconCRNX vs NAMS Comparison
Open Charts CRNX vs NAMSBanner chart's image
Crinetics Pharmaceuticals
Price$55.99
Change-$0.44 (-0.78%)
Volume$776.57K
Capitalization5.74B
NewAmsterdam Pharma
Price$31.65
Change-$0.18 (-0.57%)
Volume$466.18K
Capitalization3.59B
CRNX vs NAMS Comparison Chart in %
CRNX
Daily Signal:
Gain/Loss:
NAMS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CRNX vs. NAMS commentary
Jan 18, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Hold and NAMS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 18, 2026
Stock price -- (CRNX: $55.99 vs. NAMS: $31.65)
Brand notoriety: CRNX and NAMS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 57% vs. NAMS: 48%
Market capitalization -- CRNX: $5.74B vs. NAMS: $3.59B
CRNX [@Biotechnology] is valued at $5.74B. NAMS’s [@Biotechnology] market capitalization is $3.59B. The market cap for tickers in the [@Biotechnology] industry ranges from $111.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileNAMS’s FA Score has 1 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • NAMS’s FA Score: 1 green, 4 red.
According to our system of comparison, CRNX is a better buy in the long-term than NAMS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 4 TA indicator(s) are bullish while NAMS’s TA Score has 3 bullish TA indicator(s).

  • CRNX’s TA Score: 4 bullish, 4 bearish.
  • NAMS’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, CRNX is a better buy in the short-term than NAMS.

Price Growth

CRNX (@Biotechnology) experienced а +5.15% price change this week, while NAMS (@Biotechnology) price change was -7.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was +4.14%, and the average quarterly price growth was +42.40%.

Reported Earning Dates

CRNX is expected to report earnings on Mar 04, 2026.

NAMS is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (+1.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($5.74B) has a higher market cap than NAMS($3.59B). CRNX YTD gains are higher at: 20.279 vs. NAMS (-9.778). NAMS has higher annual earnings (EBITDA): -268.03M vs. CRNX (-474.16M). CRNX has more cash in the bank: 1.09B vs. NAMS (703M). NAMS has less debt than CRNX: NAMS (266K) vs CRNX (49.1M). NAMS has higher revenues than CRNX: NAMS (35.2M) vs CRNX (1.54M).
CRNXNAMSCRNX / NAMS
Capitalization5.74B3.59B160%
EBITDA-474.16M-268.03M177%
Gain YTD20.279-9.778-207%
P/E RatioN/AN/A-
Revenue1.54M35.2M4%
Total Cash1.09B703M155%
Total Debt49.1M266K18,459%
FUNDAMENTALS RATINGS
CRNX: Fundamental Ratings
CRNX
OUTLOOK RATING
1..100
19
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
PROFIT vs RISK RATING
1..100
40
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
38
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CRNXNAMS
RSI
ODDS (%)
Bearish Trend 3 days ago
87%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
60%
Momentum
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
45%
MACD
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
46%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
56%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
54%
Advances
ODDS (%)
Bullish Trend 4 days ago
75%
Bullish Trend 11 days ago
76%
Declines
ODDS (%)
Bearish Trend 19 days ago
76%
Bearish Trend 3 days ago
70%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
65%
Aroon
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signal:
Gain/Loss:
NAMS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RMFFX61.120.14
+0.23%
American Funds American Mutual R5
FAGKX73.250.05
+0.07%
Fidelity Growth Strategies K
MUOCX32.160.01
+0.03%
Morgan Stanley Instl US Core C
SJVAX30.68-0.08
-0.26%
Steward Large Cap Value A
GGHSX40.73-0.25
-0.61%
Invesco Health Care R6

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
-0.78%
XNCR - CRNX
56%
Loosely correlated
-3.18%
RVMD - CRNX
53%
Loosely correlated
-2.43%
IDYA - CRNX
51%
Loosely correlated
-0.61%
SRRK - CRNX
50%
Loosely correlated
-3.35%
NUVL - CRNX
50%
Loosely correlated
-1.79%
More

NAMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with IMVT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
-0.57%
IMVT - NAMS
46%
Loosely correlated
+1.04%
IDYA - NAMS
45%
Loosely correlated
-0.61%
CRNX - NAMS
44%
Loosely correlated
-0.78%
DYN - NAMS
42%
Loosely correlated
+1.74%
ROIV - NAMS
42%
Loosely correlated
-0.73%
More